Payment overview · 2025
General Payments
$1,809.22
90 reported records · 22 companies
Healthcare provider profile · identity verified
Martin John Schear, MD
Allopathic & Osteopathic Physicians|Family Medicine · DAYTON, OH · NPI 1801885355
Verified facts
What the public records show
CMS Open Payments records show Martin John Schear, MD received $1,809.22 in general payments during 2025 across 90 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Eliquis, Farxiga, Jardiance, Kerendia, Nurtec Odt, Ozempic, Rybelsus, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $396.26 | 21.9% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $298.91 | 16.5% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $213.31 | 11.8% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $154.79 | 8.6% | 11 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $143.12 | 7.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $75.54 | 4.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $74.03 | 4.1% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $60.27 | 3.3% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $57.66 | 3.2% | 2 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.45 | 2.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.46 | 2.4% | 3 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $38.22 | 2.1% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $31.45 | 1.7% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$26.21 | 1.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.88 | 1.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.57 | 1.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.18 | 1.1% | 1 | 2025 |
| VivaQuant Inc, dba Rhythm Express | Unresolved — no canonical attribution shown | $17.00 | 0.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.82 | 0.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.33 | 0.9% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $15.07 | 0.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.69 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,809.22 | 90 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $344.25 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $223.06 | 11 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $158.11 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $154.79 | 11 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $143.12 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $133.44 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $130.29 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $119.77 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $114.75 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $98.28 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $82.17 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $75.85 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $75.54 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $60.27 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $57.66 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $55.93 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.40 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $42.46 | 3 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $38.22 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $31.45 | 2 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $26.21 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| RHYTHM EXPRESS Normalized: rhythm express |
Device | VivaQuant Inc, dba Rhythm Express | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 157 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 157 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 79 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 30 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
41 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
157 | 38 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
143 | 43 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
79 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
157 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 843 | 241 |
| Amlodipine Besylate | Amlodipine Besylate | 718 | 193 |
| Atorvastatin Calcium | Atorvastatin Calcium | 621 | 183 |
| Losartan Potassium | Losartan Potassium | 489 | 128 |
| Lisinopril | Lisinopril | 441 | 129 |
| Omeprazole | Omeprazole | 295 | 87 |
| Metformin Hcl | Metformin Hcl | 291 | 76 |
| Furosemide | Furosemide | 285 | 75 |
| Simvastatin | Simvastatin | 255 | 62 |
| Fluticasone Propionate | Fluticasone Propionate | 248 | 96 |
| Metoprolol Tartrate | Metoprolol Tartrate | 237 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 220 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 218 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 199 | 60 |
| Potassium Chloride | Potassium Chloride | 193 | 46 |
| Montelukast Sodium | Montelukast Sodium | 186 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 173 | 54 |
| Buspirone Hcl | Buspirone Hcl | 164 | 40 |
| Januvia | Sitagliptin Phosphate | 163 | 34 |
| Famotidine | Famotidine | 161 | 56 |
| Eliquis | Apixaban | 157 | 35 |
| Farxiga | Dapagliflozin Propanediol | 157 | 38 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 143 | 47 |
| Symbicort | Budesonide/Formoterol Fumarate | 143 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 40 |
| Clonidine Hcl | Clonidine Hcl | 139 | 41 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 135 | 60 |
| Tizanidine Hcl | Tizanidine Hcl | 135 | 45 |
| Ibuprofen | Ibuprofen | 134 | 44 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 118 | 50 |
| Methocarbamol | Methocarbamol | 112 | 51 |
| Carvedilol | Carvedilol | 110 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 106 | 26 |
| Glimepiride | Glimepiride | 103 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 101 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 35 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 96 | 28 |
| Meloxicam | Meloxicam | 95 | 30 |
| Glipizide | Glipizide | 93 | 26 |
| Trazodone Hcl | Trazodone Hcl | 91 | 30 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 89 | 36 |
| Spironolactone | Spironolactone | 81 | 21 |
| Jardiance | Empagliflozin | 79 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 19 |
| Azithromycin | Azithromycin | 73 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 17 |
| Ozempic | Semaglutide | 69 | 16 |
| Prednisone | Prednisone | 67 | 40 |
| Niacin Er | Niacin | 66 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 65 | suppressed |
| Hydrocortisone | Hydrocortisone | 65 | 32 |
| Topiramate | Topiramate | 64 | 22 |
| Sertraline Hcl | Sertraline Hcl | 63 | 20 |
| Fluconazole | Fluconazole | 61 | 45 |
| Humalog Kwikpen U-100 | Insulin Lispro | 61 | 21 |
| Allopurinol | Allopurinol | 60 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 16 |
| Gabapentin | Gabapentin | 59 | 25 |
| Lidocaine | Lidocaine | 57 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 55 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 55 | 14 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 53 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 15 |
| Levetiracetam | Levetiracetam | 50 | 15 |
| Nitroglycerin | Nitroglycerin | 50 | 29 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 38 |
| Vascepa | Icosapent Ethyl | 48 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 47 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | suppressed |
| Novolog Flexpen | Insulin Aspart | 45 | 19 |
| Trulicity | Dulaglutide | 45 | 18 |
| Roflumilast | Roflumilast | 43 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 43 | 20 |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Finasteride | Finasteride | 42 | 11 |
| Myrbetriq | Mirabegron | 41 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 19 |
| Alendronate Sodium | Alendronate Sodium | 36 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | 11 |
| Mupirocin | Mupirocin | 34 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | 18 |
| Nifedipine Er | Nifedipine | 33 | 15 |
| Ondansetron Odt | Ondansetron | 33 | 19 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 32 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 31 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Rybelsus | Semaglutide | 30 | 12 |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 11 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 26 | 12 |
| Donepezil Hcl | Donepezil Hcl | 26 | 12 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 25 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 21 |
| Single Use Swab | Alcohol Antiseptic Pads | 25 | 13 |
| Torsemide | Torsemide | 25 | suppressed |
| Dulera | Mometasone/Formoterol | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | 11 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 19 |
| Naproxen | Naproxen | 23 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Kerendia | Finerenone | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 11 |
| Tolterodine Tartrate | Tolterodine Tartrate | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 13 |
| Atenolol | Atenolol | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Etodolac | Etodolac | 18 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 18 | 13 |
| Glipizide Er | Glipizide | 18 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 11 |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | 11 |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Mitigare | Colchicine | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Qelbree | Viloxazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,809.22 · 90 records | AstraZeneca Pharmaceuticals LP | AFREZZA, AIRSUPRA, BREZTRI, CAPLYTA, CeQur Simplicity, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, GVOKE HYPOPEN, JARDIANCE, Kerendia, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, RHYTHM EXPRESS, Rybelsus, Symbravo, TEZSPIRE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VENASEAL, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZORYVE, ZTLido | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error